AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03892278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water-based aerobic training
Description: Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and \<85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and \<85% of HRat for 1 minute.
Study NCT03892278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water-based aerobic and combined training
Description: Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and \<85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and \<85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
Study NCT03892278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
Study NCT00799214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
Study NCT02037087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good household prenatal practice
Description: Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
Study NCT02037087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care seeking
Description: * Danger-sign recognition~* Reminders for government projects
Study NCT00799214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boric acid
Description: Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
Study NCT00799214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
Study NCT02327663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24
Study NCT00029146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extracranial-intracranial bypass surgery
Description: Surgical anastomosis of a superficial temporal artery branch to a middle cerebral artery branch through a small craniectomy plus best current practice medical therapy
Study NCT00029146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: best medical therapy
Description: best current practice medical therapy
Study NCT01640834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study NCT02037087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full bank of SMS
Description: * Danger-sign recognition~* Reminders for government projects~* Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
Study NCT03738696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
Study NCT03738696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
Study NCT01640834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT01640834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02049203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ataciguat
Study NCT02049203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01640834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Administered via intramuscular injection
Study NCT03445429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-display system
Description: The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 3D-display system means that the training-set up is performed first with 3D-display system an after that with the 4K-display system.
Study NCT03445429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4K-display system
Description: The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 4K-display system means that the training-set up is performed first with 4K-display system and after that with the 3D-display system.
Study NCT02741284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Room air
Study NCT02741284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10L Oxygen by nonrebreather mask
Study NCT02705430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA and DHA capsules of 2 g/day
Description: EPA and DHA capsules of 2 g/day
Study NCT02705430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management phone application (Eco Fusion Mentally)
Description: Stress management phone application (Eco Fusion Mentally)
Study NCT02705430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: life style program using a mobile phone (Eco Mentally and NewMe)
Description: life style program using a mobile phone (Eco Mentally and NewMe)
Study NCT02705430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile phone
Description: mobile phone
Study NCT01640834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon
Description: Administered via intramuscular injection
Study NCT02326480 — intervention group
Intervention type: OTHER
Intervention: Identification of genetic causes of obesity
Description: A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition
Study NCT04179292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Therapy by Physiotherapist
Description: stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton...) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions
Study NCT04179292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Therapy as home program
Description: stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton...) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions
Study NCT02352285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
Study NCT02352285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
Study NCT04944264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management and Resiliency Training (SMART) program
Description: The Stress Management and Resiliency Training (SMART) program (bensonhenryinstitute.org) is well validated comprehensive stress management program. It is designed to cultivate both the early recognition of stress in the mind and body, develop skills to mitigate stress and evoke the relaxation response and cultivate resiliency. It is an 8 session program, typically run in a live group setting. In this study's case it was delivered via a videoconferencing platform.
Study NCT04556383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB004
Description: oral tablet
Study NCT04556383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study NCT05081297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Qigong as a traditional chinese medicine technique, composed of several types of exercises: Baduanjin, taijiquan, yijinjing, baojiangong.
Study NCT03808246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: using the demo version of a self-injector pen
Description: Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.
Study NCT01387542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone extended release (ER)
Description: Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
Study NCT02720042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phasix™ Mesh
Description: A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB)
Study NCT00959725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab (intravitreal, 2.0mg/0.05ml)
Description: One injection of intravitreal infliximab (2.0mg/0.05ml).
Study NCT03484793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AESOP service system
Description: Investigators develop an electronic reminder in CPOE system which notifies physicians when there appears to be an inappropriate prescription. At the time, a physician saves a typed prescription, our system analyzes the patient's medications, diseases and uses the knowledge base to determine whether a medication is uncommonly prescribed to all diseases in a given prescription. If the system detects the common associations of medications and diseases in a given prescription, it considers an appropriate prescription, and, if not, an actionable reminder is shown onscreen. To the right of each suggested uncommon medication is a reason why the reminder is appearing. Physicians can accept the reminder or ignore the reminder.
Study NCT01994889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
Study NCT02995148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-104)
Study NCT02995148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study NCT03197636 — intervention group
Intervention type: DRUG
Intervention: Pembrolizumab
Description: Pembrolizumab is already approved for treatment of malignant melanoma in advanced stages. We will investigate if sPD-1 or vitamin D status is changed in patients receiving pembrolizumab.
Study NCT01994889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: Tafamidis 80 mg in soft gel capsules administered once a day for 30 months
Study NCT01994889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in soft gel capsules administered once a day for 30 months
Study NCT03153722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pediatric discharge process interventions
Description: As this is an iterative quality improvement process, interventions will be evidence-based and chosen to test effectiveness for addressing areas of discharge bottlenecks or inefficiency within our specific hospital's context. Examples of possible interventions may include implementation of a discharge risk assessment (as in Statile et al, Pediatrics 2016), institution of a medications-in-hand policy on hospital discharge (as in Sauers-Ford et al, Pediatrics 2016), or initiation of a ward discharge coordinator who will help coordinate outpatient follow-up for patients. Interventions will be implemented in a stepwise fashion, utilizing successive plan-do-study-act cycles, with a minimum 2 month period between interventions to monitor outcomes.
Study NCT03060161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health in the right measure
Description: Nutritional monitoring and individual guidance on regular physical exercise.
Study NCT01898351 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat
Description: The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded.
Study NCT00335764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: given orally
Study NCT00335764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: given orally
Study NCT00335764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: given orally
Study NCT00335764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: IV administration
Study NCT01779258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycerol, paraffin (liquid and white soft)
Description: 1 application in the morning and in the evening
Study NCT01779258 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Atopiclair®
Description: 1 application in the morning, in the afternoon and in the evening
Study NCT01779258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locatop@
Description: During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days
Study NCT01779258 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Locatop@
Description: During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days
Study NCT01779258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locapred@
Description: During the 3 months study treatment:~1 application in the evening in case of flare
Study NCT01779258 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Locapred@
Description: During the 3 months study treatment:~1 application in the evening in case of flare
Study NCT00750334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Drug given Daily x 14 days and 7 days of rest for 21 day cycle
Study NCT01792544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statement
Study NCT01792544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Statement
Study NCT00272025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10mg to 20mg tablet daily for 6 weeks
Study NCT00272025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01900210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WaySafe
Study NCT01012089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Daptomycin IV 5 mg/kg one time dose
Study NCT03423199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study NCT03423199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study NCT03423199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen, 20mg, orally once daily (continuously)
Study NCT03423199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen, 20mg, orally once daily (continuously)
Study NCT03423199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks
Study NCT03423199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks
Study NCT05094778 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: a single-portal palm approach
Description: a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament.
Study NCT02439489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120-CIS
Description: BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Cisplatin will be delivered intravenously at the dose of 75 mg/m2 on day 1 every 3 weeks at each dose level of BKM120.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity
Study NCT02439489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120-CARBO
Description: BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Carboplatin will be delivered intravenously at AUC 5 on day 1 every 3 weeks at each dose level of BKM120. Should dose level 3 be completed, carboplatin will be given at AUC 6 and BKM120 at 100 mg.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity
Study NCT00625430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine
Description: Subjects within a treatment group will be administered a single transrectal intraprostatic injection of FP253.~Group A: 1 x 10Exp9 virus particles (VP); Group B: 3.2 x 10Exp9 VP; Group C: 1 x 10Exp10 VP; Group D: 3.2 x 10Exp10 VP; Group E: 1 x 10Exp11 VP; Group F: 3.2 x 10Exp 11 VP.~If there are no dose-limiting toxicities, three additional patients may be treated at the highest dose.~Twenty four hours following administration of the FP253, subjects will receive a first dose of fludarabine phosphate (20mg/m2 administered as an intravenous bolus). The first dose of fludarabine phosphate will be followed by 4 further doses at 24 hour intervals on treatment Days 3 to 6.
Study NCT00750334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Drug given Daily X 14 days and 7 days of rest for 21 day cycle
Study NCT00864071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 125 mg/5 mL Suspension, single dose
Description: A: Experimental Subjects received Alpharma formulated products under fasting conditions
Study NCT00864071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grifulvin V® 125 mg/5 mL Suspension, single dose
Description: B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions